As per the collaborative agreement, the companies will support pharmaceutical companies developing drugs that act on the central nervous system (CNS). The companies also intend to recommend each other for related work.
“Pharmaceutical formulations are often at risk of inappropriate manipulation – whether for intentional abuse or for ease of administration,” explained Judy Ashworth, MD, chief medical officer, PinneyAssociates.
Together, she told us the companies will be able to help customers which need to “push the limits” of novel formulation “in order to test its robustness and anticipate any untoward medical outcomes related to such manipulation.”
PinneyAssociates will lead the regulatory strategy and independent interpretation, while NMS Labs serves as the certified clinical and forensic reference laboratory, Ashworth explained.
As per the agreement, “Both companies have been operating independently in the area of abuse-deterrent formulation evaluations,” Ashworth said. “By teaming up, we can provide world-class strategy, implementation, and interpretation of in vitro laboratory assessments of formulations and products.”